Latest Company News

Biotechnology Corporate News

• THERATECHNOLOGIES IS PLEASED TO ANNOUNCE THE APPOINTMENT OF A NEW PRESIDENT AND CEO (Sept 01) 
• SEMBIOSYS ISSUED KEY U.S. PATENT FOR THE PRODUCTION OF APOLIPOPROTEINS IN PLANTS  (Sept 01) 
• Ceapro Announces Granting of Stock Options (Aug 31)
• Medicago named in Presidential report on meeting the challenges of pandemic influenza (AUG 31)
• Stem Cell Therapeutics Corp. Announces Funding of the Traumatic Brain Injury (TBI) Clinical Study and Issuance of Stock Options (Aug 30)
• 
  
• iCo Therapeutics Announces Second Quarter 2010 Financial Results (Aug 27)
• Bioniche & University of Ottawa Sign Exclusive Global License Agreement for Natural Health Technology (Aug 25)
  
• Jennerex Appoints Lara Longpre to Chief Operating Officer (Aug 25)

• SIRONA BIOCHEM SIGNS BINDING PRELIMINARY AGREEMENT TO ACQUIRE TFCHEM (Aug 25)

• World Health Organization Grants Prequalification to Prevenar 13*, Pfizer's 13-valent Pneumococcal Conjugate Vaccine for Infants and Young Children (Aug 23)
  
• Resverlogix Surpasses $1 Billion Trading Milestone (Aug 23)
  
• Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million  (Aug 19)
• BIONICHE: Additional Phase III Clinical Trial with UrocidinTM Expected to Commence in 2010 (Aug 19)
  
• Stem Cell Therapeutics Corp.: Traumatic Brain Injury (TBI) Clinical Study Gains IRB Approval at University of Calgary (Aug 13)
  
• Microbix Reports 11% Growth In Product Volume For Nine Month (Aug 12)
• Warnex Reports Second Quarter 2010 Results: 18% Increase in Quarterly Revenue, $1.0 Million Improvement on Operating Profit (Aug 12)
  
• Cardiome Reports Second Quarter Results and Updates Guidance (Aug 11)
  
• Valeant and Biovail Set Date for Shareholders Meetings (Aug 11)
• Allon Therapeutics Releases Second Quarter Operating Results (Aug 11)
  
• Medicago announces an increase of its previously announced equity offering to $7.5 million (Aug 10)
• Medicago awarded $21 million from the U.S. Department of Defense (Aug 10)
• YM BioSciences granted Orphan Drug Designation for CYT387 (Aug 10)
  
• Miraculins Launches ELISA Kit for Detection of PSP94 in Urine and Announces Distribution Agreement With GenWay Biotech (Aug 10)
  
• Elan And Transition Therapeutics Announce Topline Summary Results Of Phase 2 Study and Plans for Phase 3 for ELND005 (Scyllo-inositol) (Aug 09)
• Miraculins Executes Final Agreement to Acquire PREVUTM Skin Cholesterol Test (Aug 05)
  
• Theratechnologies to present at both BMO and Canaccord Genuity Conferences (Aug 3)
• Cynapsus Announces Formation of Clinical Advisory Board For Parkinson’s Program (Aug 5)
• Cynapsus Announces Additional Debenture Financing (Aug 4)
• OncoGenex to Webcast Second Quarter Financial Results on Thursday, August 5, 2010 (Jul 29)
• Cynapsus Announces Addition of Dr. Albert Agro to Parkinson’s Program Team (Jul 29)
• Immunovaccine Appoints Albert Scardino as New Board Member
   (Jul 29)
• OncoGenex to Webcast Second Quarter Financial Results on Thursday, August 5, 2010 (Jul 29)
• Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients (Jul 28)
• Cynapsus Announces Parkinson’s Disease Survey Results (Jul 27)
  
• Cynapsus Announces Signing of License Option Agreement of Parkinson’s Disease Technology (Jul 26)
• Biovail Announces Second-Quarter 2010 Earnings Release, Conference-Call Details (Jul 26)
  
• Lab Research enters into preferred provider agreement with large Japanese pharma company (Jul 26)
• iCo Therapeutics Inc. receives Health Canada Clearance to Conduct Phase II DME Trial with iCo-007 (Jul 26)
  
• Kane Biotech Appoints Dr. Jeffrey B. Kaplan to Scientific Advisory Board (Jul 20) 
• Dalton Pharma Services Names New Sales and Marketing Manager (Jul 20)
• LAB Research adds five additional global pharma to its client list (Jul 20)
• Ceapro Announces Debt Reduction (Jul 16)
  
• CRITICAL OUTCOME TECHNOLOGIES INC. REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER  AND THE YEAR ENDED APRIL 30, 2010 (Jul 15)
• Monsanto Gets Green Light to Expand Seed Manufacturing Facility in Lethbridge, Alberta  (Jul 15)
• Amorfix Life Sciences announces global licensing agreement for the treatment of ALS with Biogen Idec (Jul 15)
  
• Codexis and CO2 Solution Unveil Carbon Capture Program (Jul 15)
  
• MaRS celebrates successful one-year anniversary of Angel program
  Over fifty percent of MaRS clients have received funding  (Jul 15)
• Amorfix A(4) Assay Provides New Insights Into Alzheimer's Disease Pre-clinical Development Mouse Models (Jul 15)
• Immunovaccine Licenses Clinical Stage Cancer Vaccine from Merck KGaA (Jul 15)